Surgery to Improve Survival in Isolated Tricuspid Regurgitation

Patients with isolated tricuspid regurgitation (i.e., who have no associated left-sided valve disease) are frequently treated conservatively. In many cases, valve disease is highly symptomatic, even with the optimization of medical treatment; however, an invasive strategy is seldom proposed.

Cirugía para mejorar la sobrevida en insuficiencia tricuspidea aislada

The aim of this work was to measure the impact of surgery on isolated tricuspid regurgitation compared to medical treatment alone.

Researchers conducted a retrospective analysis of 3276 patients with pure tricuspid regurgitation who were included in an echocardiography database between November 2001 and March 2016. All-cause mortality for patients who underwent surgery versus those who received medical treatment alone was compared using propensity score matching to balance baseline differences.

Among 3276 patients with isolated tricuspid regurgitation, only 171 (5%) underwent surgery (143 for valve repair and 28 for valve replacement). The remaining 3105 patients were managed with medical treatment.


Read also: Do NOACs Result in Any Benefit in TAVR?


Upon analysis, there were no differences between the patients who underwent surgery and those who did not (hazard ratio [HR]: 1.34; p = 0.288).

In the surgical subgroup, there were no differences between repair and replacement surgery patients (HR: 1.53; p = 0.254).

Conclusion

Patients with isolated tricuspid regurgitation do not benefit from surgery in terms of long-term survival compared to medical treatment alone.

Original Title: Surgery Does Not Improve Survival in Patients With Isolated Severe Tricuspid Regurgitation.

Reference: Andrea L. Axtell et al. J Am Coll Cardiol 2019;74:715–25.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...